These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 32492831)
1. The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia. Muñoz M; Coveñas R J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492831 [TBL] [Abstract][Full Text] [Related]
2. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant. Coveñas R; Rodríguez FD; Robinson P; Muñoz M Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914 [TBL] [Abstract][Full Text] [Related]
3. Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo. Wu H; Cheng X; Huang F; Shao G; Meng Y; Wang L; Wang T; Jia X; Yang T; Wang X; Fu C Drug Des Devel Ther; 2020; 14():2413-2422. PubMed ID: 32606608 [TBL] [Abstract][Full Text] [Related]
4. The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer? Muñoz M; Coveñas R Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32962202 [TBL] [Abstract][Full Text] [Related]
5. Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload. Ge C; Huang H; Huang F; Yang T; Zhang T; Wu H; Zhou H; Chen Q; Shi Y; Sun Y; Liu L; Wang X; Pearson RB; Cao Y; Kang J; Fu C Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19635-19645. PubMed ID: 31488714 [TBL] [Abstract][Full Text] [Related]
6. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes. Liu X; Zhu Y; Zheng W; Qian T; Wang H; Hou X Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1628-1634. PubMed ID: 31010320 [TBL] [Abstract][Full Text] [Related]
7. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680 [TBL] [Abstract][Full Text] [Related]
8. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy? Robinson P; Coveñas R; Muñoz M Curr Med Chem; 2023; 30(16):1798-1812. PubMed ID: 35959620 [TBL] [Abstract][Full Text] [Related]
9. Neurokinin-1 Receptor Antagonists against Hepatoblastoma. Muñoz M; Rosso M; Coveñas R Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31466222 [TBL] [Abstract][Full Text] [Related]
10. The NK-1R Antagonist Aprepitant Prevents LPS-Induced Oxidative Stress and Inflammation in RAW264.7 Macrophages. Zhao XN; Bai ZZ; Li CH; Sheng CL; Li HY Drug Des Devel Ther; 2020; 14():1943-1952. PubMed ID: 32546961 [TBL] [Abstract][Full Text] [Related]
11. The NK-1 receptor antagonist L-732,138 induces apoptosis in human gastrointestinal cancer cell lines. Muñoz M; Rosso M; Coveñas R Pharmacol Rep; 2017 Aug; 69(4):696-701. PubMed ID: 28550801 [TBL] [Abstract][Full Text] [Related]
12. Advances in the research and application of neurokinin-1 receptor antagonists. Hong X; Ma J; Zheng S; Zhao G; Fu C J Zhejiang Univ Sci B; 2024 Feb; 25(2):91-105. PubMed ID: 38303494 [TBL] [Abstract][Full Text] [Related]
13. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280 [TBL] [Abstract][Full Text] [Related]
14. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. Muñoz M; González-Ortega A; Coveñas R Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581 [TBL] [Abstract][Full Text] [Related]
15. Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists. Molinos-Quintana A; Trujillo-Hacha P; Piruat JI; Bejarano-García JA; García-Guerrero E; Pérez-Simón JA; Muñoz M Invest New Drugs; 2019 Feb; 37(1):17-26. PubMed ID: 29721755 [TBL] [Abstract][Full Text] [Related]
16. Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation. Cao X; Yang Y; Zhou W; Wang Y; Wang X; Ge X; Wang F; Zhou F; Deng X; Miao L BMC Cancer; 2023 May; 23(1):471. PubMed ID: 37221457 [TBL] [Abstract][Full Text] [Related]
17. Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach. Muñoz M; Rosso M; Coveñas R Mini Rev Med Chem; 2020; 20(5):408-417. PubMed ID: 31721701 [TBL] [Abstract][Full Text] [Related]
18. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Muñoz M; Rosso M Invest New Drugs; 2010 Apr; 28(2):187-93. PubMed ID: 19148578 [TBL] [Abstract][Full Text] [Related]
19. The Potential In Vitro Inhibitory Effects of Neurokinin-1 Receptor (NK-1R) Antagonist, Aprepitant, in Osteosarcoma Cell Migration and Metastasis. Alsaeed MA; Ebrahimi S; Alalikhan A; Hashemi SF; Hashemy SI Biomed Res Int; 2022; 2022():8082608. PubMed ID: 36177059 [TBL] [Abstract][Full Text] [Related]
20. The neurokinin-1 receptor antagonist aprepitant ameliorates oxidized LDL-induced endothelial dysfunction via KLF2. Zheng J; Chen K; Zhu Y; Wang H; Chen Z; Yong X; Yin H; Chen J; Lai K; Liu Y Mol Immunol; 2019 Feb; 106():29-35. PubMed ID: 30576949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]